৳ 30/unit
Pack: ৳ 300
৳ 30/unit
Pack: ৳ 300
At a glance
Brivaracetam is an antiepileptic medication used for the treatment of partial-onset seizures in patients 1 month of age and older. It binds to synaptic vesicle protein 2A (SV2A) in the brain with high affinity, suppressing abnormal nerve activity and preventing the spread of seizures.
Indications
- Partial-onset seizures in patients 1 month of age and older
Pharmacology
Brivaracetam is an anticonvulsant that binds with high selectivity and 15-30 times greater affinity to synaptic vesicle protein 2A (SV2A) in the brain. This binding reduces pre-synaptic neurotransmitter release and suppresses abnormal neuronal activity. The drug rapidly crosses the blood-brain barrier and is quickly absorbed after oral administration.
Dosage
Adults (16 years and older): Initial dose: 50 mg twice daily (100 mg/day). Maintenance: 25-100 mg twice daily (50-200 mg/day).
Children (weight ≥50 kg): Initial: 25-50 mg twice daily (50-100 mg/day). Maintenance: 25-100 mg twice daily (50-200 mg/day).
Children (weight 20 to <50 kg): Initial: 0.5-1 mg/kg twice daily (1-2 mg/kg/day). Maintenance: 0.5-2 mg/kg twice daily (1-4 mg/kg/day).
Children (weight 11 to <20 kg): Initial: 0.5-1.25 mg/kg twice daily (1-2.5 mg/kg/day). Maintenance: 0.5-2.5 mg/kg twice daily (1-5 mg/kg/day).
Children (weight <11 kg): Initial: 0.75-1.5 mg/kg twice daily (1.5-3 mg/kg/day). Maintenance: 0.75-3 mg/kg twice daily (1.5-6 mg/kg/day).
Hepatic impairment (all stages): Reduce starting dose to 25 mg twice daily and do not exceed 75 mg twice daily (150 mg/day).
Renal impairment: Mild-moderate: No dose adjustment. ESRD (dialysis): Not studied.
Elderly: Start at the low end of the dosing range.
IV administration: When oral administration is temporarily not feasible, same dose and frequency IV (up to 4 consecutive days).
Side effects
Common side effects (≥5% and at least 2% more frequent than placebo): Somnolence/sedation, dizziness, fatigue, nausea/vomiting.
Other common: Headache, constipation, irritability, anxiety, nervousness, aggression, agitation, restlessness, depression, abnormal behavior.
Serious (rare): Stevens-Johnson syndrome, toxic epidermal necrolysis (potentially fatal skin reactions), bronchospasm, angioedema (hypersensitivity reactions), suicidal thoughts or behavior.
Side effects are more common during the first few weeks and usually lessen as the body adjusts to the medication.
Use in pregnancy
Adequate data on use during pregnancy are not available; animal studies show potential fetal harm. Use during pregnancy only if clearly needed (benefit to mother outweighs potential risk to fetus). Patients taking brivaracetam during pregnancy are encouraged to participate in a pregnancy exposure registry.
Precautions & warnings
- Antiepileptic drugs, including brivaracetam, increase the risk of suicidal thoughts or behavior; monitor patients for changes in mood or behavior.
- May cause somnolence, fatigue, dizziness, and coordination disturbances; advise patients not to drive or operate machinery.
- Psychiatric adverse reactions (non-psychotic: irritability, anxiety, aggression, agitation, depression; psychotic: hallucinations, paranoia) may occur; monitor patients.
- Do not stop abruptly due to risk of increased seizure frequency and status epilepticus; withdraw gradually.
- Caution in hepatic impairment (dose adjustment may be needed).
- Use during pregnancy only if clearly needed (animal studies show potential fetal harm).
- Limited data on breastfeeding; brivaracetam is excreted in breast milk; monitor exclusively breastfed infants for drowsiness, agitation, weight gain, and developmental milestones.
Overdose effects
Overdose symptoms: Vertigo, balance disorder, fatigue, nausea, diplopia, anxiety, bradycardia. No specific antidote; standard medical practice for overdose management: maintain adequate airway, oxygenation and ventilation; monitor cardiac rate and rhythm and vital signs.
Storage conditions
Store below 30°C in a dry place, protected from light. Keep out of reach of children. Oral solution: Discard any unused portion remaining after 5 months of first opening.